March 2025

Burden and determinants of multi-b/tsDMARD failure in psoriatic arthritis

Arthritis Research & Therapy 2025;27:46 doi: 10.1186/s13075-025-03518-7

Haberman et al. analysed prescribing patterns and characteristics of PsA patients with
multi-b/tsDMARD failure, defined as requiring ≥4 b/tsDMARDs. Among 960 patients at the NYU Psoriatic Arthritis Centre, 17% met this criterion. These patients were more likely to be female, obese, and have higher rates of axial involvement and depression. They also exhibited greater disease activity, suggesting that both inflammatory and non-inflammatory factors contribute to multiple treatment failures.

Keywords:

February 2025

Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: An open-label extension of randomized clinical trials

JAMA Dermatology 2025;161:56–66 doi: 10.1001/jamadermatol.2024.4688

Armstrong et al. evaluated the long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis over a three-year period. The study found that exposure-adjusted incidence rates of AEs remained stable or declined over time, with no new safety signals emerging. Clinical response rates, including PASI75/90, were maintained, supporting the drug’s long-term efficacy.

Keywords:

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis

Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005

Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.

Keywords:

Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies

J Rheumatol 2025. Epub ahead of print doi: 10.3899/jrheum.2024-0923

Gladman et al. assessed the impact of bimekizumab over 1 year on patient-reported symptoms, HRQoL, and work productivity in patients with PsA who were bDMARD-naïve or TNF-IR. The study showed that bimekizumab treatment resulted in sustained improvements across multiple domains, including pain, fatigue, physical function, and work impairment.

Keywords:

January 2025

A randomised phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement

J Am Acad Dermatol 2024;91:1150–7 doi: 10.1016/j.jaad.2024.07.1521

Lebwohl et al. investigated the efficacy and safety of risankizumab compared with placebo for treating palmoplantar psoriasis. At Wk16, significantly more patients receiving risankizumab achieved palmoplantar Investigator’s Global Assessment (ppIGA) 0/1 and PPASI75. The results were sustained through Wk52 with no new safety signals.

Keywords:

December 2024

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

Acta Derm Venereol. 2024 20;104:adv40737 doi: 10.2340/actadv.v104.40737

Renkhold et al. report that secukinumab significantly reduced psoriasis-associated pruritus intensity, improved skin lesions, and normalised histopathological changes, with stable neuroanatomy despite treatment discontinuation.

Keywords:

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494.

McInnes et al. assessed the efficacy of guselkumab over 48 weeks in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors. The results demonstrated consistent improvements in joint, skin, and patient-reported outcomes across all baseline-defined subgroups. Guselkumab showed greater efficacy compared with placebo at Week 24, with responses maintained or improved through Week 48.

Keywords:

Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis

J Dermatol. 2024;51:1559–1571 doi: 10.1111/1346-8138.17448

Tsai et al. conducted a systematic literature review and network meta-analysis evaluating deucravacitinib and other systemic treatments for moderate-to-severe plaque psoriasis in Asian populations. The authors reported that deucravacitinib achieved PASI75 and PASI90 response rates of 66% and 40%, respectively, higher than placebo and apremilast.

Keywords:

November 2024

Interleukin-23 vs. interleukin-12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network

J Am Acad Dermatol 2024 Nov;91:889–895 doi: 10.1016/j.jaad.2024.07.1473

Tsai et al. observed no significant difference in the incidence of psoriatic arthritis among psoriasis patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors, although there was a numerically lower PsA risk with IL-23 inhibitors. Results indicate both therapies are similarly effective for PsO management.

Keywords:

Persistent patient-level effect of guselkumab at consecutive 8-week dosing visits and over time in patients with active psoriatic arthritis: post hoc analysis of a 2-year, Phase 3, randomized, controlled study

ACR Open Rheumatol. 2024 doi 10.1002/acr2.11732 Epub ahead of print

Mease et al. conducted a post-hoc analysis of the phase 3 DISCOVER-2 trial to assess the persistence of clinically relevant improvements with guselkumab in biologic-naïve patients with PsA. The analysis showed that guselkumab maintained clinical improvements in joint and skin domains at consecutive dosing visits (Q8W) and over time.

Keywords: